CUE
Cue Biopharma, Inc.
+1.55 (+4.55%)35.73USD50.8K成交股數260M市值–本益比(近四季)6.9股價營收比+166.7%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 7.9M+167% | 5.7M+1251% | 21.9M+558% | 2.1M-19% | 3.0M+72% | 421K-77% | 3.3M+59% | 2.7M+92% | 1.7M | 1.8M | 2.1M | 1.4M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 49.0M | 6.9M | 16.5M | 4.8M | 7.9M | 8.5M | 9.4M | 9.5M | 10.2M | 10.9M | 9.9M | 10.7M |
| 銷售管理費用 | 46.6M | 4.2M | 3.5M | 4.9M | 3.7M | 4.2M | 2.9M | 3.5M | 4.2M | 4.6M | 3.6M | 4.2M |
| 營業利益 | −87.7M+916% | −5.4M-56% | 2.0M-122% | −7.6M-27% | −8.6M-32% | −12.3M-11% | −8.8M-23% | −10.4M-23% | −12.7M | −13.8M | −11.4M | −13.5M |
| 營業利益率 | -1,113.3% | -94.1% | 9.0% | -353.4% | -292.3% | -2,921.4% | -264.2% | -390.6% | -737.8% | -759.6% | -543.8% | -978.1% |
| 稅後淨利 | −153M+1705% | −5.2M-58% | 1.6M-118% | −7.4M-27% | −8.5M-31% | −12.3M-9% | −8.7M-21% | −10.2M-23% | −12.3M | −13.4M | −11.0M | −13.2M |
| 淨利率 | -1,943.2% | -91.1% | 7.2% | -346.6% | -287.1% | -2,911.4% | -259.6% | -382.7% | -719.1% | -737.7% | -524.0% | -954.1% |
| 稀釋 EPS | -24.14+804% | -1.08-78% | 7.41-4459% | -0.07-65% | -2.67+968% | -4.95+1607% | -0.17-29% | -0.20-31% | -0.25 | -0.29 | -0.24 | -0.29 |
| 稀釋股數 | 6.3M | 4.8M | 94.7M | 101M | 3.2M | 2.5M | 51.2M | 50.2M | 49.5M | 45.8M | 46.4M | 44.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 17.4M | 16.4M | 27.1M | 11.7M | 27.5M | 13.1M | 32.4M | 30.0M | 41.0M | 48.5M | 54.7M | 52.9M |
| 應收帳款 | 5.4M | 5.4M | 5.5M | 387K | 532K | 0.00 | 3.2M | 1.8M | 1.4M | 1.7M | 1.7M | 1.1M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 30.7M | 30.9M | 42.2M | 31.6M | 40.7M | 22.3M | 44.8M | 42.3M | 54.0M | 61.5M | 68.9M | 73.2M |
| 有息負債 | – | – | – | – | – | – | 1.3M | 2.3M | 3.2M | 4.2M | 5.2M | 6.1M |
| 總負債 | 28.4M | 9.3M | 15.8M | 18.4M | 22.5M | 15.7M | 19.4M | 20.7M | 23.9M | 24.4M | 26.2M | 27.2M |
| 股東權益 | 2.3M | 21.6M | 26.4M | 13.2M | 18.2M | 6.6M | 25.4M | 21.6M | 30.0M | 37.1M | 42.7M | 46.0M |
| 負債比 | 92.5% | 30.0% | 37.4% | 58.1% | 55.4% | 70.4% | 43.4% | 48.9% | 44.3% | 39.7% | 38.1% | 37.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | 31.1M | 27.7M | 37.8M | 44.3M | 49.5M | 46.8M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −10.9M+34% | – | – | – | −8.2M | – | – | −9.8M | – | – | – |
| 資本支出 | – | 121K | – | – | – | 150K | – | – | 55K | – | – | – |
| 自由現金流 | – | −11.1M+33% | – | – | – | −8.3M | – | – | −9.8M | – | – | – |
| 折舊攤銷 | – | 566K | – | – | – | 101K | – | – | 99K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -194.6% | – | – | – | -1,976.7% | – | – | -573.0% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 27.5M | +195.7% | −26.6M | -96.9% | -0.28 | −21.9M |
| FY2024 | 9.3M | +69.2% | −40.7M | -438.0% | -0.72 | −36.4M |
| FY2023 | 5.5M | +341.0% | −50.7M | -924.1% | -1.11 | −40.0M |
| FY2022 | 1.2M | -91.7% | −53.0M | -4,257.8% | -1.49 | −42.0M |
| FY2021 | 14.9M | +373.7% | −44.2M | -295.6% | -1.41 | −39.8M |
| FY2020 | 3.2M | -8.8% | −44.8M | -1,419.8% | -1.56 | −33.1M |
| FY2019 | 3.5M | +202.7% | −36.7M | -1,061.2% | -1.66 | −30.8M |
| FY2018 | 1.1M | – | −23.2M | -2,033.4% | -1.94 | −28.3M |